SAR445877

Phase 2Small molecule

Sanofi

SAR445877 is one of 75 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Gastric CancerNot yet recruiting

Solid TumorRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Not yet recruiting

Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

SAR445877

Sanofi

Phase 2

1 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT05584670

Q3 2028

Phase 2Not yet recruiting

Gastric Cancer

NCT07692204

Q1 2030

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT07133425

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07133425·29 enrolled

Gastric Cancer1 trial

A Phase 2, Open-label, Dose Optimization/Expansion Study of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Gastric or Gastroesophageal Junction Cancer

Not yet recruiting· Sanofi logo

Sanofi·Phase 2·NCT07692204·30 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT05584670·542 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SAR445877. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR445877 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR445877. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR445877

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q1 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Gastric Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News